Thai Translation and Validation of Chronic Rhinosinusitis-Patient Reported Outcome (CRS-PRO)
2
Issued Date
2026-01-01
Resource Type
ISSN
20958811
eISSN
25891081
Scopus ID
2-s2.0-105033058448
Journal Title
World Journal of Otorhinolaryngology Head and Neck Surgery
Rights Holder(s)
SCOPUS
Bibliographic Citation
World Journal of Otorhinolaryngology Head and Neck Surgery (2026)
Suggested Citation
Chitsuthipakorn W., Pooldum V., Phetpong J., Lawpoolsri S., Kanjanawasee D., Kowatanamongkon P., Mongkolkul K., Seresirikachorn K., Snidvongs K. Thai Translation and Validation of Chronic Rhinosinusitis-Patient Reported Outcome (CRS-PRO). World Journal of Otorhinolaryngology Head and Neck Surgery (2026). doi:10.1002/wjo2.70101 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/115871
Title
Thai Translation and Validation of Chronic Rhinosinusitis-Patient Reported Outcome (CRS-PRO)
Corresponding Author(s)
Other Contributor(s)
Abstract
Objectives: The Chronic Rhinosinusitis Patient-Reported Outcome (CRS-PRO) questionnaire was recently developed for use in chronic rhinosinusitis (CRS) patients. This instrument was developed using current diagnostic criteria. This study aimed to translate and validate CRS-PRO for Thai CRS patients. Methods: The three-phase translation process and validation were conducted at Rajavithi Hospital, a tertiary hospital in Bangkok, Thailand. Adults (> 18 years) with primary CRS, diagnosed using EPOS2020 criteria, were recruited alongside non-CRS controls. Discriminant validity was assessed by comparing scores between CRS patients and non-CRS controls. Concurrent validity was evaluated by correlating CRS-PRO with the Thai version of the Sinonasal Outcome Test-22 (SNOT-22). Reliability was assessed using internal consistency (Cronbach's alpha) and test–retest reliability using intraclass correlation coefficient (ICC). Results: A total of 85 CRS patients and 40 non-CRS controls were enrolled. The Thai CRS-PRO was completed in (101.80 ± 26.36) seconds. CRS patients had significantly higher scores than controls (16 [10–24] vs. 2 [0–5], p < 0.001) (median [IQR]). CRS-PRO demonstrated strong concurrent validity with SNOT-22 (ρ = 0.82, p < 0.001), high internal consistency (Cronbach's alpha = 0.89), and high test–retest reliability (ICC = 0.81, 95% confidence interval 0.72–0.88). Conclusions: The Thai-translated CRS-PRO has been developed and validated. It demonstrated significant discriminant validity between patients and non-patients, a very strong correlation with the Thai version of SNOT-22, and good reliability. Its brevity and time efficiency support its applicability in both clinical practice and research, enhancing its potential for widespread adoption.